Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease

References

• Makhlof A, Tozuka Y, Takeuchi H. pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur J Pharm Biopharm. 2009;72:1–8.
   PubMed Web of Science ®Google Scholar
• Klein S, Stein J, Dressman J. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model. J Pharm Pharmacol. 2005;57:709–719.
   PubMed Web of Science ®Google Scholar
• Rodrigeuz M, Antunez JA, Taboada C, et al. Colon-specific delivery of budesonide from microencapsulated cellulosic cores: evaluation of the efficacy against colonic inflammation in rats. J Pharm Pharmacol. 2001;53:1207–1215.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Yamamoto H, Takeuchi H, et al. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther. 2005;315:196–202.
   PubMed Web of Science ®Google Scholar
• Lamprecht A. Multiparticulate systems in the treatment of inflammatory bowel disease. Curr Drug Targets Inflamm Allergy. 2003;2:137–144.
   PubMedGoogle Scholar
• Patel M, Shah T, Amin A. Therapeutic opportunities in colon specific drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2007;24:147–202.
   PubMed Web of Science ®Google Scholar
• Patel M, Amin A. Recent trends in microbially and/or enzymatically driven colon-specific drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2011;28:489–552.
   PubMed Web of Science ®Google Scholar
• Patel MM. Cutting-edge technologies in colon-targeted drug delivery systems. Expert Opin Drug Deliv. 2011;8:1247–1258.
   PubMed Web of Science ®Google Scholar
• Patel MM. Colon targeting: an emerging frontier for oral insulin delivery. Expert Opin Drug Deliv. 2013;10:731–739.
   PubMed Web of Science ®Google Scholar
• Patel MM. Getting into the colon: approaches to target colorectal cancer. Expert Opin Drug Deliv. 2014;11:1343–1350.
   PubMed Web of Science ®Google Scholar
• Patel MM. Colon: a gateway for chronotherapeutic drug delivery systems. Expert Opin Drug Deliv. 2015;12:1389–1395.
   PubMed Web of Science ®Google Scholar
• Patel MM. Micro/nano-particulate drug delivery systems: a boon for the treatment of inflammatory bowel disease. Expert Opin Drug Deliv. 2016;13:771–775.
   PubMed Web of Science ®Google Scholar
• Youshia J, Lamprecht A. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases. Expert Opin Drug Deliv. 2015;4:1–14.
   Google Scholar
• Moulari B, Béduneau A, Pellequer Y, et al. Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. J Control Release. 2014;188:9–17.
   PubMed Web of Science ®Google Scholar
• Xiao B, Laroui H, Ayyadurai S, et al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapy. Biomaterials. 2013;34:7471–7482.
   PubMed Web of Science ®Google Scholar
• Wileman TE, Lennartz MR, Stahl PD. Identification of the macrophage mannose receptor as a 175-kDa membrane protein. Proc Natl Acad Sci USA. 1986;83:2501–2505.
   PubMed Web of Science ®Google Scholar
• Sinhmar KG, Shah NN, Chokshi NV, et al. Process, optimization, and characterization of budesonide loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease. Drug Dev Ind Pharm. 2018. DOI:10.1080/03639045.2018.1434194
   PubMed Web of Science ®Google Scholar
• Kumar PV, Asthana A, Dutta T, et al. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target. 2006;14:546–556.
   PubMed Web of Science ®Google Scholar
• Jain A, Agarwal A, Majumder S, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release. 2010;148:359–367.
   PubMed Web of Science ®Google Scholar
• Patel MM, Amin AF. Process, optimization and characterization of mebeverine hydrochloride loaded guar gum microspheres for irritable bowel syndrome. Carbohydr Polym. 2011;86:536–545.
   Web of Science ®Google Scholar
• Patel MM, Amin AF. Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer. Drug Deliv. 2011;18:281–293.
   PubMed Web of Science ®Google Scholar
• Patel MM, Amin AA. Design and optimization of colon targeted system of theophylline for chronotherapy of nocturnal asthma. J Pharm Sci. 2011; 100:1760–1772.
   PubMed Web of Science ®Google Scholar
• Patel MM, Amin AF. Development of a novel tablet-in-capsule formulation of mesalamine for inflammatory bowel disease. Pharm Dev Technol. 2013;18:390–400.
   PubMed Web of Science ®Google Scholar
• Patel MM, Patel SL, Bhadani MN, et al. A synchronous colon specific drug delivery system for orally administered mesalamine. Acta Pharm Sci. 2009;51:251–260.
   Google Scholar
• Patel MM, Shah TJ, Amin AF, et al. Design, development and optimization of a novel time and pH-dependent colon targeted drug delivery system. Pharm Dev Technol. 2009;14:62–69.
   PubMed Web of Science ®Google Scholar
• Patel MM. Formulation and development of di-dependent microparticulate system for colon-specific drug delivery. Drug Deliv Transl Res. 2017;7:312–324.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Ubrich N, Yamamoto H. 1990. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2001;299:775–781.
   PubMed Web of Science ®Google Scholar
• Beloqui A, Coco R, Alhouayek M, et al. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. Int J Pharm. 2013;454:775–783.
   PubMed Web of Science ®Google Scholar
• Geboes K, Ridell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404–409.
   PubMed Web of Science ®Google Scholar
• Hoshimoto A, Suzuki Y, Katsuno T, et al. Caprylic acid and medium-chain triglycerides inhibit IL-8 gene transcription in Caco-2 cells: comparison with the potent histone deacetylase inhibitor trichostatin A. Brit J Pharmcol. 2002;136:280.
   PubMed Web of Science ®Google Scholar
• Kono H, Enomoto N, Connor HD, et al. Medium-chain triglycerides inhibit free radical formation and TNF-alpha production in rats given enteral ethanol. Am J Physiol Gastrointest Liver Physiol. 2000;278:G467–G476.
   PubMed Web of Science ®Google Scholar
• Ralph P, Nakoinz I. Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line. Nature. 1975;257:393–394.
   PubMed Web of Science ®Google Scholar
• Boirivant M, Fuss IJ, Chu A, et al. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med. 1998;188:1929–1939.
   PubMed Web of Science ®Google Scholar
• Panaccione R. Mechanisms of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2013;9:529–532.
   PubMedGoogle Scholar
• Gasche C, Lomer MCE, Cavill I, et al. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53:1190–1197.
   PubMed Web of Science ®Google Scholar
• Lech M, Susanti HE, Römmele C, et al. Quantitative expression of C-type lectin receptors in humans and mice. Int J Mol Sci. 2012; 13:10113–10131.
   PubMed Web of Science ®Google Scholar
• Lepenies B, Lee J, Sonkaria S. Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv Drug Deliv Rev. 2013;65:1271–1281.
   PubMed Web of Science ®Google Scholar
• Ekstrom GM. Oxazolone-induced colitis in rats: effects of budesonide, cyclosporine A and 5- aminosalicylic acid. Scand J Gastroenterol. 1998;33:174–179.
   PubMed Web of Science ®Google Scholar
• Yasukawa K, Tokuda H, Tun X, et al. The detrimental effect of nitric oxide on tissue is associated with inflammatory events in the vascular endothelium and neutrophils in mice with dextran sodium sulfate-induced colitis. Free Radic Res. 2012;46:1427–1436.
   PubMed Web of Science ®Google Scholar
• Gan HT, Chen YQ, Ouyang Q. Sulfasalazine inhibits activation of nuclear factor-kappaB in patients with ulcerative colitis. J Gastroenterol Hepatol. 2005;20:1016–1024.
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429.
   PubMed Web of Science ®Google Scholar
• Mendoza JL, Abreu MT. Biological markers in inflammatory bowel disease: practical consideration for clinicians. Gastroenterol. Clin Biol. 2009;33:S158–S173.
   PubMedGoogle Scholar
• Marchal Bressenot A, Riddell RH, Boulagnon-Rombi C, et al. Review article: the histological assessment of disease activity in ulcerative colitis. Aliment Pharmacol Ther. 2015;42:957–967.
   PubMed Web of Science ®Google Scholar
• Zhang YW, Ding LS, Lai MD. Reg gene family and human diseases. World J Gastroenterol. 2003;9:2635–2641.
   PubMed Web of Science ®Google Scholar
• Carvalho A, Giovannini G, De Luca A, et al. Dectin-1 isoforms contribute to distinct Th1/Th17 cell activation inmucosal candidiasis. Cell Mol Immunol. 2012;9:276–286.
   PubMed Web of Science ®Google Scholar
• Mizoguchi A. Healing of intestinal inflammation by IL-22. Inflamm Bowel Dis. 2012;18:1777–1784.
   PubMed Web of Science ®Google Scholar
• Dadwal NA, Hallan SS, Sharma S, et al. Development of enteric-coated microspheres of embelin for their beneficial pharmacological potential in ulcerative colitis. Artif Cells Nanomed Biotechnol. 2017;45:1–9.
   PubMed Web of Science ®Google Scholar
• Rahman M, Kumar V, Beg S, et al. Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art. Artif Cells Nanomed Biotechnol. 2016;44:1597–1608.
   PubMed Web of Science ®Google Scholar
• Zong S, Pu Y, Li S, et al. Beneficial anti-inflammatory effect of paeonol self-microemulsion-loaded colon-specific capsules on experimental ulcerative colitis rats. Artif Cells Nanomed Biotechnol. 2018;1–12. DOI:10.1080/21691401.2017.1423497
   PubMed Web of Science ®Google Scholar
• Parihar AKS, Srivastava S, Patel S, et al. Novel catalase loaded nanocores for the treatment of inflammatory bowel diseases. Artif Cells Nanomed Biotechnol. 2017;45:981–989.
   PubMed Web of Science ®Google Scholar
• Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol. 2016;44:27–40.
   PubMed Web of Science ®Google Scholar